Wockhardt’s Zaynich™ Successfully Treats Drug-Resistant Infection in US Pediatric Cancer Patient

Wockhardt Limited ( (IN:WOCKPHARMA) ) just unveiled an announcement.

Wockhardt Limited announced the successful treatment of a 15-year-old US patient with Acute Myeloid Leukemia who had a severe, drug-resistant infection. The patient was treated with Zaynich™ (Zidebactam/Cefepime, WCK 5222) under compassionate use, after failing to respond to multiple antibiotics. This case highlights the potential of Zaynich™ in combating drug-resistant infections, as it has successfully treated 51 patients with life-threatening Gram-negative infections. The drug, which has completed a global Phase III study, is designed to target multi-drug resistant infections and is set to support its marketing authorization worldwide.

More about Wockhardt Limited

Wockhardt Limited is a pharmaceutical and biotechnology company focused on developing innovative antibiotics for multi-drug resistant infections. The company has a strong emphasis on creating treatments for Gram-negative infections and has been involved in drug discovery for over 25 years.

YTD Price Performance: -2.39%

Average Trading Volume: 37,235

Current Market Cap: 231.3B INR

See more insights into WOCKPHARMA stock on TipRanks’ Stock Analysis page.